 |
|
|
| |
GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for at Least 12 Weeks
|
| |
| |
Reported by Jules Levin EASL 2012 Apr 18-22 Barcelona Spain
I. Jacobson1, E. Lawitz2, J. Lalezari3, I. Crespo4, M. Davis5, T. Hassanein6, M. DeMicco7, S. Arora8, N, Gitlin9, R. Herring10, D.R. Nelson11, J.K. Anderson12, R.H. Hyland12,
R.G. Hindes12, E. Albanis12, W.T. Symonds12, M.M. Berrey13
1Weill Cornell Medical College, New York, NY; 2Alamo Medical Research, San Antonio, TX; 3Quest Clinical Research, San Francisco, CA; 4Advanced Research Institute, Trinity, FL; 5South Florida Center of Gastroenterology, Wellington, FL;
6Southern California Liver Center, Coronado CA; 7Advanced Clinical Research Institute, Anaheim, CA; 8University of New Mexico Health Science Center, Albuquerque, NM; 9Atlanta Gastroenterology Associates, Atlanta, GA; 10Nashville Gastrointestinal Specialists, Nashville, TN; 11University of Florida, Gainesville, FL; 12Gilead Sciences, Inc., Foster City, CA 13 Pharmasset, Inc., Princeton, NJ, USA
|
| |
|
|
|
|
|
